US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kurv Yield Premium Strategy Tesla TSLA ETF

25.53

-0.0500-0.20%

Post-market: 25.530.00000.00%17:35 EST

Volume:10.07K

Turnover:257.35K

Market Cap:23.74M

PE:- -

High:25.78

Open:25.78

Low:25.42

Close:25.58

52wk High:32.81

52wk Low:15.36

Shares:930.00K

Float Shares:930.00K

Volume Ratio:0.80

T/O Rate:1.08%

Dividend:8.75

Dividend Rate:34.28%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI

Upstream Bio to Participate in Upcoming December Investor Conferences

Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

CSTONE PHARMA-B (02616): ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Academic Debut

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TSLP"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TSLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","market":"US","secType":"STK","nameCN":"Kurv Yield Premium Strategy Tesla TSLA ETF","latestPrice":25.53,"timestamp":1766178000000,"preClose":25.58,"halted":0,"volume":10073,"hourTrading":{"tag":"盘后","latestPrice":25.53,"preClose":25.53,"latestTime":"17:35 EST","volume":20,"amount":511.7,"timestamp":1766183751511},"delay":0,"floatShares":930000,"shares":930000,"eps":0,"marketStatus":"Market Closed","change":-0.05,"latestTime":"12-19 16:00:00 EST","open":25.78,"high":25.78,"low":25.42,"amount":257348.469112,"amplitude":0.014073,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":25.58,"sharesOutstanding":930000,"nav":25.55,"aum":23761500,"dividendRate":0.342769,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":26.03,"preClose":25.58,"latestTime":"08:04 EST","volume":4,"amount":104.16,"timestamp":1766149499952},"postHourTrading":{"tag":"盘后","latestPrice":25.53,"preClose":25.53,"latestTime":"17:35 EST","volume":20,"amount":511.7,"timestamp":1766183751511},"volumeRatio":0.8047455409139854,"impliedVol":0.2749,"impliedVolPercentile":0.26},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","floatShares":930000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8047455409139854,"shares":930000,"dividePrice":8.7509,"high":25.78,"amplitude":0.014073,"preClose":25.58,"low":25.42,"week52Low":15.36,"pbRate":"--","week52High":32.81,"institutionHeld":0,"latestPrice":25.53,"eps":0,"divideRate":0.342769,"volume":10073,"delay":0,"ttmEps":0,"open":25.78,"prevYearClose":30.27,"prevWeekClose":24.5399,"prevMonthClose":23.84,"prevQuarterClose":24.56,"fiveDayClose":24.5399,"twentyDayClose":22.1863,"sixtyDayClose":23.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TSLP\",params:#limit:5,,,undefined,":[{"date":"2025-12-03","symbol":"TSLP","amount":0.5,"announcedDate":"2025-12-02","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-03","defaultRemindTime":1764772200000,"name":"TSLA收益溢价策略ETF-Kurv","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-04","payableDate":"2025-12-03","currency":"USD","dateTimestamp":1764738000000,"payDate":"2025-12-04"},{"date":"2025-11-05","symbol":"TSLP","amount":0.5,"announcedDate":"2025-11-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-05","defaultRemindTime":1762353000000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-06","payableDate":"2025-11-05","currency":"USD","dateTimestamp":1762318800000,"payDate":"2025-11-06"},{"date":"2025-10-08","symbol":"TSLP","amount":0.5,"announcedDate":"2025-10-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-08","defaultRemindTime":1759930200000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-09","payableDate":"2025-10-08","currency":"USD","dateTimestamp":1759896000000,"payDate":"2025-10-09"},{"date":"2025-09-03","symbol":"TSLP","amount":0.45,"announcedDate":"2025-09-02","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-03","defaultRemindTime":1756906200000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-04","payableDate":"2025-09-03","currency":"USD","dateTimestamp":1756872000000,"payDate":"2025-09-04"},{"date":"2025-08-06","symbol":"TSLP","amount":0.45,"announcedDate":"2025-08-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-06","defaultRemindTime":1754487000000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-07","payableDate":"2025-08-06","currency":"USD","dateTimestamp":1754452800000,"payDate":"2025-08-07"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TSLP\",market:\"US\",,,undefined,":[{"executeDate":"2023-11-22","recordDate":"2023-11-24","paymentDate":"2023-11-27","value":0.5775,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-22","value":0.6664,"currency":"USD"},{"executeDate":"2024-01-24","recordDate":"2024-01-25","paymentDate":"2024-01-26","value":0.5555,"currency":"USD"},{"executeDate":"2024-02-21","recordDate":"2024-02-22","paymentDate":"2024-02-23","value":0.313,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-22","value":0.5189,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TSLP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TSLP\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588213877","title":"Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2588213877","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588213877?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:00","pubTimestamp":1764586800,"startTime":"0","endTime":"0","summary":"SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies. GB-0895 is an antibody optimized using AI to achieve ultra-high-affinity TSLP binding, extended half-life, and high specificity. It is being developed as a long-acting therapy designed for dosing every six months to help reduce the treatment burden for people with severe asthma. GB-0895 is also being evaluated in a Phase 1 clinical trial in chronic obstructive pulmonary disease .Phase 1 Results Presented at ERS 2025Dave Singh, MD, professor of clinical pharmacology and respiratory medicine at the University of Manchester and medical director at the Medicines Evaluation Unit, presented Phase 1 data for GB-0895 at the European Respiratory Society  International Congress 2025 in Amsterdam. In this study of 96 people with mild to moderate asthma, GB-0895 was generally well tolerated across a wide dose range , demonstrated dos","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/generatebiomedicines-to-initiate-global-phase-3-studies-of-gb-0895-a-long-acting-anti-tslp-antibody-for-severe-asthma-engineered-with-ai-302628300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP"],"gpt_icon":0},{"id":"2586420640","title":"Upstream Bio to Participate in Upcoming December Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2586420640","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586420640?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:00","pubTimestamp":1764072000,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Nov.  25, 2025  (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194193/0/en/Upstream-Bio-to-Participate-in-Upcoming-December-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP"],"gpt_icon":0},{"id":"2582852875","title":"Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582852875","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582852875?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:10","pubTimestamp":1762776600,"startTime":"0","endTime":"0","summary":"Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026. Interim Phase 1 results of APG333 in healthy volunteers reported today exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6-month dosing and the development of a quarterly or less frequently dosed co-formulation of APG273  for respiratory indications. Completed $345 million public offering; $913 million cash, cash equivalents and marketable securities pro forma as of September 30 supports runway into 2H 2028. Phase 1b data in asthma, AD data from APEX 52-week Part A anticipated in. -- At this year's European Academy of Dermatology a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139","TSLP","LU2065732104.USD","PRGS","BK4097"],"gpt_icon":0},{"id":"1160394698","title":"CSTONE PHARMA-B (02616): ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Academic Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1160394698","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160394698?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:14","pubTimestamp":1762474478,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) announced that the company will present its autoimmune and inflammation pipeline candidate CS2015 (OX40L/TSLP bispecific antibody) at the 2025 American College of Allergy,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","TSLP","BK1574","02616"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TSLP\",params:#limit:6,delay:false,,,undefined,":[]}}